DNLI vs PNR · rev $3.6M vs P/E 18, rev $4.18B
Denali Therapeutics Inc (DNLI) versus Pentair PLC (PNR) — a side-by-side from cached financials, not a winner call.
Denali Therapeutics Inc (DNLI) is a biotechnology company listed on US.
Pentair PLC (PNR) is a specialty industrial machinery company listed on NYSE.
Latest reported DNLI revenue for 2026-06-30 was $3.6M. Net income was -$256.0M. DNLI currently screens at market cap $2.11B.
Latest reported PNR revenue for 2025-12-31 was $4.18B. Net income was $653.8M. Revenue was up 2.3% from 2024-12-31 to 2025-12-31. PNR currently screens at market cap $11.86B and trailing P/E 18.4.
DNLI currently screens at market cap $2.11B. PNR currently screens at market cap $11.86B and trailing P/E 18.4.
Not investment advice. Open the DNLI and PNR stock pages for the full models.
Not investment advice.